GeoVax Labs, Inc. — 2017 Form 10-K
Reporting period: Fiscal year ended December 31, 2017. This is an annual report, not a quarterly filing. GeoVax is a clinical-stage vaccine developer with no product sales; reported revenue primarily reflects government grants and collaboration funding.
Business context and pipeline
GeoVax develops vaccines using its MVA-VLP platform. Its programs cover preventive vaccines for HIV, Zika, hemorrhagic fever viruses and malaria, and therapeutic candidates for hepatitis B and cancer. The clade B preventive HIV vaccine was the most advanced program: Phase 2a was completed and the HVTN 114 follow-on trial began in January 2017. Other programs were preclinical or earlier-stage. The company relies on collaborators, government support, and third-party manufacturers and clinical networks.
Financial performance and liquidity
| Metric | 2017 | 2016 |
|---|---|---|
| Grant and collaboration revenue | $1.075 million | $829,000 |
| Research and development expense | $2.017 million | $1.971 million |
| General and administrative expense | $1.232 million | $2.131 million |
| Net loss | $2.170 million | $3.272 million |
| Net loss per common share | $0.03 | $0.08 |
| Net cash used in operating activities | $1.688 million | $1.946 million |
- Revenue increased about 30%; it included $980,270 in government grant and contract revenue and a $95,000 AGT collaboration fee. Revenue was recognized as eligible costs were incurred. The company reported no product revenue.
- Net loss narrowed about 34%. G&A declined, mainly because 2016 included $912,862 of warrant-modification stock compensation; R&D rose about 2%.
- Cash and cash equivalents were $312,727 at year-end, down from $454,030. Total assets were $490,235; current liabilities were $811,292, producing a $363,218 working-capital deficit. Stockholders’ equity was a $321,057 deficiency.
- Accrued management salaries and director fees totaled $715,235 and were being deferred. Operating cash use was partly offset by $1.552 million of financing proceeds from preferred stock and warrant exercises.
- No material long-term debt was reported at year-end. In February 2018, the company issued a $50,000, five-year note bearing 5% interest. No profit or operating margin is meaningful as a measure of commercial performance given the absence of product sales and the cost-reimbursement nature of much of the revenue.
Material changes, outlook, and risks
- The company said existing cash and grant support were expected to fund planned operations only into the third quarter of 2018. It needed additional capital thereafter and warned that unavailable or unfavorable financing could force delays, reductions, or termination of programs.
- The auditor’s report included a going-concern paragraph, citing recurring operating losses and liabilities exceeding assets. The auditor nevertheless gave an unqualified opinion on the financial statements; management’s plans did not eliminate substantial doubt about continuing as a going concern.
- In 2017, GeoVax raised $980,000 net from Series D preferred stock and $571,511 from warrant exercises. After year-end, it raised $600,000 through Series E preferred stock and obtained the $50,000 note. The March 2018 Series E shares were convertible at $0.08 per share, subject to adjustment.
- Management expected a Phase 1 HIV vaccine/protein study to begin in the second half of 2018. It also described planning for a larger HIV efficacy trial, subject to study results and NIAID support; this was not a firm commitment or assured funding.
- Key risks include the need for continuing external financing, clinical and regulatory uncertainty, dependence on government grants and third parties, manufacturing constraints, competition, and potential dilution. At December 31, 2017, common shares reserved for potential issuance totaled approximately 245.9 million, primarily for convertible preferred stock and equity awards.
- Subsequent developments included 20 million common shares issued upon conversion of Series D preferred stock in January and February 2018, and a separate 5 million-share issuance in February under a financial advisory agreement. Outstanding common shares were 131,736,810 as of March 22, 2018.
Important facts for investors to verify
- Current cash runway, grant availability, and status and terms of any additional financing; compare the stated third-quarter 2018 runway with subsequent filings.
- Progress, enrollment, results, and funding for HVTN 114 and the planned HIV studies, as well as any changes to NIAID or HVTN support.
- Actual and potential dilution from preferred-stock conversion terms, anti-dilution provisions, options, and subsequent share issuances.
- Whether deferred salaries and director fees are paid, and whether the company can meet current obligations without curtailing research programs.
- Clinical, manufacturing, regulatory, and collaboration milestones and whether preclinical results translate into human safety and efficacy.